Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 168 • 2018 ACR/ARHP Annual Meeting
IgG Anti-High-Density Lipoproteins Antibodies Discriminate between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients
Irene Cecchi¹, Massimo Radin², Elena Rubini³, Ana Suárez⁴, Dario Roccatello⁵, Savino Sciascia⁶ and Javier Rodríguez-Carrio⁷, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁴Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ⁷Bone and Mineral Research Unit, Instituto Reina Sofía de Investigación Nefrológica, REDinREN del ISCIII, Hospital Universitario Central de Asturias, Oviedo, Spain
Background/Purpose: Reliable biomarkers for risk stratification in Antiphospholipid Syndrome (APS) are still lacking. Anti-high-density lipoproteins antibodies (anti-HDL) showed promising results in predicting the development of…
Abstract Number: 171 • 2018 ACR/ARHP Annual Meeting
Flow Cytometric Assessment of the Mammalian Target of Rapamycin Pathway Using Antiphospholipid Syndrome As a Disease Model
Ariel Badger¹, Ecem Sevim², Oral Alpan³ and Doruk Erkan⁴, ¹O&O Alpan Medical Center, Fairfax, VA, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Allergy & Immunology, O&O Alpan Medical Center, Fairfax, VA, ⁴Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY
Background/Purpose: The mammalian target of rapamycin (mTOR) is a component of MTOR complex-1 that, when activated by upstream molecule protein kinase B (AKT) and another…
Abstract Number: 172 • 2018 ACR/ARHP Annual Meeting
Serum Chemokines and miRNA Levels and Its Association with Cumulative Organ Damage in Patients with Antiphospholipid Syndrome: A Bench to Bedside Study
Laura-Aline Martinez-Martinez¹, Fausto Sanchez-Muñoz², Maya Jazmin Nastia Nicte Chacon-Perez², Yaneli Juarez-Vicuña², Nicole Mouneu Ornelas¹, Anthony Beltran-Cortez², Ricardo Alberto Venegas Yañez³, Julio Fonseca Basurto¹, Evelyn Aranda Cano¹, Mary Carmen Amigo⁴ and Luis M. Amezcua-Guerra¹, ¹Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ²Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ³Reumatologia, Instituto Nacional de Cardiología "Ignacio Chavez", Ciudad de México, Mexico, ⁴Rheumatology, Centro Medico ABC, Mexico, Mexico
Background/Purpose: Recent evidence suggests that chemokines and miRNAs are involved in the pathogenesis of antiphospholipid syndrome (APS). However, the specific role of these molecules in…
Abstract Number: 174 • 2018 ACR/ARHP Annual Meeting
Rivaroxaban Versus Warfarin As Secondary Thromboprophylaxis in Patients with Antiphospholipid Syndrome: A Randomized, Multicenter, Open-Label, Clinical Trial
Josefina Cortés-Hernández¹, Luis Sáez-Comet², Antoni Riera Mestre³, A. Castro Salomó⁴, J. Cuquet Pedragosa⁵, Vera Ortiz-Santamaría⁶, M. Mauri Plana⁷ and Josep Ordi-Ros⁸, ¹Internal Medicine Department, Vall d´Hebron Hospital, Barcelona, Spain, ²Internal Medicine, Miguel Servet University Hospital, Zaragoza, Spain, ³VTE Unit. Internal Medicine, Bellvitge University Hospital, Barcelona, Spain, ⁴Hospital Universitari de Reus, Spain, Reus, Spain, ⁵Internal Medicine, Granollers University Hospital, Granollers, Spain, ⁶Rheumatology, Hospital General. Granollers., Granollers, Spain, ⁷Internal Medicine, Mataró Hospital, Mataró, Spain, ⁸Internal Medicine, Vall d'Hebron Hospital, Barcelona, Spain
Background/Purpose: Long-term anticoagulation with vitamin K antagonists (VKAs) is the standard of care in thrombotic antiphospholipid syndrome (APS) but requires frequent monitoring and dose adjustment.…
Abstract Number: 851 • 2018 ACR/ARHP Annual Meeting
Integrin Mac-1 Potentiates Neutrophil Adhesion and NET Release in Antiphospholipid Syndrome
Gautam Sule¹, William J. Kelley¹, Srilakshmi Yalavarthi¹, Alison Banka¹, Andrew Vreede², Omolola Eniola-Adefeso¹ and Jason S. Knight³, ¹University of Michigan, Ann Arbor, MI, ²Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ³., University of Michigan, Ann Arbor, MI
Background/Purpose: While the role of antiphospholipid antibodies in activating endothelial cells has been extensively studied, the impact of these antibodies on the adhesive potential of…
Abstract Number: 17 • 2017 ACR/ARHP Annual Meeting
Thrombotic Events in Pediatric Systemic Lupus Erythematosus: A Preliminary Analysis of a Large, Single-Center Cohort
Jennifer Rammel¹, Martha Curry² and Marietta M. de Guzman³, ¹Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ³Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: While pediatric systemic lupus erythematosus (pSLE) represents only 20% of all SLE cases, pSLE patients often have more aggressive disease with multi-organ involvement. These…
Abstract Number: 108 • 2017 ACR/ARHP Annual Meeting
Impact of Antiphospholipid Syndrome Ibook on Medical Students’ Improvement of Knowledge: An International Randomized Controlled Experimental Study
Stephane Zuily¹, Laurent Phialy², Eloïse Germain², Ozan Unlu³, Virginie Dufrost⁴, Isabelle Clerc-Urmès⁴, Jessica R. Berman⁵, Michael Lockshin⁶, Denis Wahl⁷ and Doruk Erkan⁸, ¹Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, CHRU de Nancy, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Auto-Immune Diseases; Inserm U1116; Lorraine University, Nancy, France, ²Lorraine University, Nancy School of Medicine, Nancy, France, ³Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Nancy Academic Hospital, Nancy, France, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Hospital for Special Surgery, NYC, NY, ⁷CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, Nancy, France, ⁸Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY
Background/Purpose: iBooks, a free electronic book application by Apple, is well-suited for publishing interactive medical texts. To date, no iBook on Antiphospholipid Syndrome (APS) exists,…
Abstract Number: 1295 • 2017 ACR/ARHP Annual Meeting
Pregnancy Outcome in Patients with SLE Compared to Patients with Other Inflammatory Rheumatic Diseases: Real World Data from a Prospective Pregnancy Register
Rebecca Fischer-Betz¹, Christina Bungartz², Matthias Schneider¹, Jutta Richter¹, Anja Weiss², Angela Zink³ and Anja Strangfeld⁴, ¹Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany, ⁴Epidemiology, German Rheumatism Research Center, Berlin, Germany
Background/Purpose: SLE pregnancies are complicated due to risk for maternal disease exacerbation and potential for fetal and neonatal complications. With careful pre-pregnancy counseling and monitoring…
Abstract Number: 2564 • 2017 ACR/ARHP Annual Meeting
Inhibition of Neutrophil Elastase Protects Against Glomerulonephritis and Thrombosis in a Mouse Model of Lupus
Gautam Sule¹, Levi F. Mazza¹, Nayef M. Kazzaz¹, Srilakshmi Yalavarthi¹, He Meng¹ and Jason S. Knight², ¹University of Michigan, Ann Arbor, MI, ²., University of Michigan, Ann Arbor, MI
Background/Purpose: Neutrophils are potential instigators of autoimmunity and effectors of organ damage in lupus. However, there is presently no consensus as to whether inhibition of…
Abstract Number: 2759 • 2017 ACR/ARHP Annual Meeting
The Risk of Ischaemic Stroke in Primary APS Patients: A Prospective Study
Massimo Radin¹, Karen Schreiber², Irene Cecchi³, Dario Roccatello⁴, Maria Jose Cuadrado⁵ and Savino Sciascia⁶, ¹Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁵St Thomas Hospital, Lupus Research Unit, London, United Kingdom, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: The antiphospholipid syndrome(APS)is an autoimmune condition characterized by thrombosis and/or pregnancy morbidity andpersistent positivityfor antiphospholipid antibodies(aPL). The most common neurological manifestation of APS is…
Abstract Number: 2761 • 2017 ACR/ARHP Annual Meeting
Adenosine Receptor Agonism Protects Against Antiphospholipid Antibody-Mediated Netosis and Venous Thrombosis
Ramadan A. Ali¹, He Meng¹, Srilakshmi Yalavarthi¹, Yogendra Kanthi¹ and Jason S. Knight², ¹University of Michigan, Ann Arbor, MI, ²., University of Michigan, Ann Arbor, MI
Background/Purpose: We have previously reported that antiphospholipid antibodies (aPL) activate neutrophils and thereby exaggerate neutrophil extracellular trap release (NETosis), which potentially contributes to the thrombotic…
Abstract Number: 2762 • 2017 ACR/ARHP Annual Meeting
Study of 60 Patients with Intrauterine Fetal Deaths Related to Antiphospholipid Syndrome
Mériem Belhocine¹, Laetitia Coutte², Nicolas Martin Silva³, Nathalie Morel⁴, Gaelle Guettrot-Imbert⁴, Romain Paule⁴, Michel Dreyfus⁵, Micaela Fredi⁶, Odile Souchaud-Debouverie⁷, Jean Charles Piette⁸, Veronique Le Guern⁴ and Nathalie Costedoat-Chalumeau¹, ¹Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ²Department of Internal Medicine, Department of Internal Medicine, Cochin University Hospital, paris, France, ³Department of Internal Medicine, Department of Internal Medicine, University Hospital Center of Caen, Caen, France, ⁴Department of Internal Medicine, Department of Internal Medicine, Cochin University Hospital, Paris, France, ⁵Department of Gynecology and Obstetrics, Department of Gynecology and Obstetrics, University Hospital Center of Caen, Caen, France, ⁶Department of Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ⁷Department of Internal Medicine, Department of Internal Medicine, Poitiers University Hospital, Poitiers, France, ⁸Department of Internal Medicine, Department of Internal Medicine, University Hospital Pitié-Salpétrière, Paris, France
Background/Purpose: The antiphospholipid syndrome (APS) is defined by a combination of arterial and/or venous thrombosis, pregnancy morbidity, and persistent antiphospholipid antibodies. There is a real…
Abstract Number: 1 • 2017 ACR/ARHP Annual Meeting
Anti-Phosphatidylserine/Prothrombin Antibodies (aPS/PT) As Potential Diagnostic Markers and Risk Predictors of Venous Thrombosis and Obstetric Complications in Antiphospholipid Syndrome
Hui Shi¹, Qiongyi Hu², Hui Zheng², Jialin Teng², Gary Norman³, Jinfeng Zhou⁴ and Chengde Yang², ¹Department of Rheumatology and Immunology, Ruijin Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, ²Ruijin Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, ³INOVA Diagnostics, Inc, San Diego, China, ⁴Werfen China, Shanghai, China
Background/Purpose: , Methods: , Results: and Conclusion: Background/Purpose:The antiphospholipid syndrome (APS) is a thrombophilic disorder characterized by clinical manifestations of vascular thrombosis and obstetric complications…
Abstract Number: 2 • 2017 ACR/ARHP Annual Meeting
Identifying “Second Hit” Risk Factor(s) Associated with Thrombosis and Pregnancy Morbidity in Ethnically Diverse Antiphospholipid Antibodies Positive Patients
Yu Zuo¹, Jennifer Fan², Ravi Sarode¹, Song Zhang², Una E. Makris¹, David Karp³ and Yu-min Shen², ¹University of Texas Southwestern Medical Center, Dallas, TX, ²University of Texas Southwestern Medical Center, dallas, TX, ³Rheumatology, UT Southwestern Med Ctr, Dallas, TX
Background/Purpose: The evaluation of thrombotic and pregnancy risks associated with antiphospholipid antibodies (aPL) in individual patients without APS clinical manifestation is challenging. Our aim is…
Abstract Number: 5 • 2017 ACR/ARHP Annual Meeting
Clinical Utility of the Global Antiphospholipid Syndrome Score (GAPSS) for Risk Stratification: A Pooled Analysisfrom 2273 Patients
Savino Sciascia¹, Massimo Radin², Giovanni Sanna³, Irene Cecchi⁴, Dario Roccatello⁵ and Maria Laura Bertolaccini⁶, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ²Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Louise Coote Lupus Unit, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, London, United Kingdom, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁶Academic Department of Vascular Surgery, Cardiovascular Division, King's College London, United Kingdom, London, United Kingdom
Background/Purpose: Recently, our group conceived a risk score for clinical manifestations of APS [the global APS score or GAPSS] that takes into account the combination…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].